D-altruronic acid | 21675-51-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-altruronic acid
• 英文别名: altruronic acid；D-Altruronsaeure；(2S,3S,4R,5S)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid
• CAS: 21675-51-4
• 化学式: C₆H₁₀O₇
• 分子量: 194.141
• InChiKey: IAJILQKETJEXLJ-STGXQOJASA-N

物化性质

• 沸点：
  553.4±50.0 °C(Predicted)
• 密度：
  1.748±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  135
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 水 作用下， 生成 D-altruronic acid
  参考文献：
  名称：

  Niemann; Karjala; Link, Journal of Biological Chemistry, 1934, vol. 104, p. 190

  摘要：

  DOI：

文献信息

• CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
  申请人：Bapat Abhijit S.

  公开号：US20140364595A1

  公开（公告）日：2014-12-11

  The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; or (iv) (AFA) m″ -X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.

  该发明提供了由至少一种抗真菌剂或抗菌剂与至少一种连接剂和/或载体偶联形成的基于共轭的抗真菌或抗菌前药。这些前药的公式为：(i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; 或 (iv) (AFA) m″ -X，其中：AFA是抗真菌剂或抗菌剂；L是载体；X是连接剂；m范围从1到10；n范围从2到10；m′为1到10；p为1到10；n′为1到10；q为1到10，前提是q'和n不同时为1；m″为1到10。该发明还提供了包含基于共轭的前药的纳米粒子。此外，该发明还提供了以纳米粒子形式的非共轭抗真菌和抗菌剂。
• [EN] PROCESSES FOR PREPARING ALDARIC, ALDONIC, AND URONIC ACIDS<br/>[FR] PROCÉDÉS DE PRÉPARATION D'ACIDES ALDARIQUES, ALDONIQUES ET URONIQUES
  申请人：ARCHER DANIELS MIDLAND CO

  公开号：WO2021101834A1

  公开（公告）日：2021-05-27

  Various processes for preparing aldaric acids, aldonic acids, uronic acids, and/or lactone(s) thereof are described. For example, processes for preparing a C5-C6 aldaric acid and/or lactone(s) thereof by the catalytic oxidation of a C5-C6 aldonic acid and/or lactone(s) thereof and/or a C5-C6 aldose are described.

  描述了制备阿尔达酸、醛酸、糖醛酸和/或内酯的各种过程。例如，描述了通过催化氧化C5-C6醛酸和/或糖醛酸和/或内酯以及C5-C6醛糖制备C5-C6阿尔达酸和/或内酯的过程。
• IMMUNITY INDUCER FOR SACCHARIDE ANTIGENS
  申请人：NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY

  公开号：US20160074522A1

  公开（公告）日：2016-03-17

  The present invention provides an immunity inducer and an immunity inducing method using same. The immunity inducer has an immunopotentiation effect on any target oligosaccharide antigen, in particular oligosaccharide antigens included in mammal-derived glycoprotein N-linked sugar chains; is capable of providing a monoclonal antibody having high specificity to and affinity with target oligosaccharide antigens; and has as an effective component thereof a glycolipid including a target oligosaccharide antigen (R) and indicated by general formula (2), or a salt thereof. General formula (2): R—Z—Y—CH(NH—CO—(CH 2 ) n1 —CH 3 )—(CH 2 ) n2 —CH 3 (in the formula, R indicates a straight-chain or branched oligosaccharide comprising 2-30 of at least one type of monosaccharide. Z indicates a single bond, O, S or NH, a linker bound to thiomethyl, amino methylated sugar alcohol. Y indicates —(CH 2 ) m —. n1 indicates an integer of 2-40, n2 indicates an integer of 1-27, and m indicates an integer of 1-30).

  本发明提供了一种免疫诱导剂和使用该免疫诱导剂的免疫诱导方法。该免疫诱导剂对任何目标寡糖抗原具有免疫增强效果，特别是对哺乳动物来源的糖蛋白N-连接糖链中包含的寡糖抗原具有免疫增强效果；能够提供具有高特异性和亲和力的单克隆抗体以及有效成分为包括目标寡糖抗原（R）的糖脂，由通式（2）表示，或其盐。通式（2）：R—Z—Y—CH（NH—CO—（CH2）n1—CH3）—（CH2）n2—CH3（在公式中，R表示由至少一种单糖组成的直链或支链寡糖，包括2-30个单糖。Z表示单键，O，S或NH，与硫甲基化，氨基甲基化糖醇结合的连接物。Y表示—（CH2）m—。n1表示2-40的整数，n2表示1-27的整数，m表示1-30的整数）。
• Bioavailability and improved delivery of alkaline pharmaceutical drugs
  申请人：——

  公开号：US20040214215A1

  公开（公告）日：2004-10-28

  Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compositions provide improved bioavailability and improved delivery of the drug into the cutaneous tissues.

  本发明实施例涉及一种组合物、制备该组合物的过程以及使用该组合物。该组合物包括碱性药物和至少一种选择自羟酸、多羟酸、相关酸、内酯或其组合物的分子复合物。该组合物提供了改善的生物利用度和将药物输送至皮肤组织的改善输送。
• Topical Delivery System for Cosmetic and Pharmaceutical Agents
  申请人：Gupta K. Shyam

  公开号：US20060110415A1

  公开（公告）日：2006-05-25

  This invention relates to topical compositions containing esters of hydroxy acids and their application in the deep-penetration delivery of beneficial cosmetic and pharmaceutical agents.

  本发明涉及含有羟基酸酯的局部组成物，以及它们在深层渗透输送有益的化妆品和药物剂的应用。